Physician profile
Victor E Ghantous
NPI 1356363253
$1,886.58
in general payments reported to CMS, 2019-2025
18 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $173 · 2022: $569 · 2023: $65.56 · 2024: $381 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.47 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $294.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $273.09 | 2020-2024 | Farxiga |
| Calliditas Therapeutics US INC. | $217.28 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $170.26 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $146.37 | 2021-2025 | Jynarque |
| Amgen INC. | $125.22 | 2020-2024 | Tavneos |
| Opko Pharmaceuticals, LLC | $121.09 | 2022-2025 | Rayaldee |
| Vifor Pharma, INC. | $110.36 | 2021-2024 | Veltassa |
| Glaxosmithkline, LLC. | $94.94 | 2021-2022 | |
| Travere Therapeutics, INC. | $67.66 | 2024-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.23 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $47.67 | 2021 | |
| Genzyme Corporation | $45.84 | 2022-2024 | |
| Akebia Therapeutics INC | $45.08 | 2024-2025 | Vafseo |
| Kyowa Kirin, INC. | $28.54 | 2024 | Crysvita |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.85 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $15.88 | 2025 | Velphoro |
| Alnylam Pharmaceuticals INC. | $15.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Ghantous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.